Genprex, Inc. Files 8-K with Corporate Updates
Ticker: GNPX · Form: 8-K · Filed: Aug 13, 2024 · CIK: 1595248
Sentiment: neutral
Topics: corporate-filing, 8-K
Related Tickers: GNPX
TL;DR
Genprex filed an 8-K on Aug 13 detailing corporate info. Nothing major, just housekeeping.
AI Summary
Genprex, Inc. filed an 8-K on August 13, 2024, reporting other events and financial statements. The filing details the company's corporate structure, including its incorporation in Delaware and its principal executive offices located at 3300 Bee Cave Road, #650-227, Austin, TX 78746. The company's IRS Employer Identification Number is 90-0772347.
Why It Matters
This filing provides essential corporate information and updates for Genprex, Inc., which is crucial for investors and stakeholders to understand the company's structure and reporting status.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not appear to contain significant new risks or material adverse information.
Key Players & Entities
- Genprex, Inc. (company) — Registrant
- August 13, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- 3300 Bee Cave Road, #650-227, Austin, TX 78746 (address) — Principal executive offices
- 90-0772347 (identifier) — I.R.S. Employer Identification Number
- 512-537-7997 (phone_number) — Registrant's telephone number
FAQ
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is August 13, 2024.
In which state is Genprex, Inc. incorporated?
Genprex, Inc. is incorporated in Delaware.
What is the principal executive office address for Genprex, Inc.?
The principal executive offices are located at 3300 Bee Cave Road, #650-227, Austin, TX 78746.
What is Genprex, Inc.'s IRS Employer Identification Number?
The IRS Employer Identification Number for Genprex, Inc. is 90-0772347.
What is the registrant's telephone number?
The registrant's telephone number, including area code, is (512) 537-7997.
Filing Stats: 1,062 words · 4 min read · ~4 pages · Grade level 13.8 · Accepted 2024-08-13 08:38:12
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share GNPX The Nasdaq Capital Ma
Filing Documents
- gnpx20240803_8k.htm (8-K) — 32KB
- 0001437749-24-026166.txt ( ) — 163KB
- gnpx-20240813.xsd (EX-101.SCH) — 3KB
- gnpx-20240813_def.xml (EX-101.DEF) — 11KB
- gnpx-20240813_lab.xml (EX-101.LAB) — 15KB
- gnpx-20240813_pre.xml (EX-101.PRE) — 11KB
- gnpx20240803_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On August 13, 2024, Genprex, Inc. ("Genprex" or the "Company") issued a press release in which it announced that the Singapore Patent Office has granted a patent to Genprex that covers the use of the Company's lead drug candidate, Reqorsa (quaratusugene ozeplasmid) Gene Therapy, in combination with anti-PD-1 antibodies through 2037. The Company also noted that the patent expands on the previously granted patents in the U.S., Japan, Mexico, Russia, Australia, Chile, China and Korea to cover the use of REQORSA in combination with an immune checkpoint inhibitor, i.e., PD-1 antibodies. The granted Korean patent also claims the use of REQORSA in combination with PD-L1 antibodies. Genprex will be pursuing additional patent applications with claims to combinations of REQORSA and PD-L1 antibodies in the U.S., Brazil, Canada, China, Europe and Israel. Should these applications grant, they would be applicable to Genprex's Acclaim-3 clinical trial, which is a Phase 1/2 clinical trial that uses a combination of REQORSA and Genentech's Tecentriq as maintenance therapy for patients with extensive stage small cell lung cancer (ES-SCLC) who developed tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. The Acclaim-3 clinical trial has received U.S. Food and Drug Administration ("FDA") Fast Track Designation for this patient population and Acclaim-3 has also received an FDA Orphan Drug Designation. Cautionary Language Concerning Forward-Looking Statements
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GENPREX, INC. Date: August 13, 2024 By: /s/ Ryan Confer Ryan Confer Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer)